Literature DB >> 11276297

Efficacy and safety of a Ginkgo biloba extract.

P L Le Bars1, J Kastelan.   

Abstract

This review of the literature documents the efficacy of a standard extract of Ginkgo biloba (EGb) in managing signs and symptoms associated with memory disorders and dementia. Analysis of the discrepant findings reveals that study outcomes may vary with the type of population studied, the outcome measurements selected, and the dosing tested. Overall, the efficacy of EGb was more frequently reported in trials enrolling dementia patients than healthy volunteers. In contrast to narrow memory tests, broad cognitive assessments were more likely to detect the treatment effect. Although a dose--response relationship is not yet established, 240 mg day(-1) EGb seems to show a higher rate of treatment response than does 120 mg day(-1). Regarding safety, in all trials reviewed the adverse event profile of EGb was not different from that of the placebo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11276297     DOI: 10.1017/s1368980000000574

Source DB:  PubMed          Journal:  Public Health Nutr        ISSN: 1368-9800            Impact factor:   4.022


  5 in total

1.  Ginkgo Biloba Extract Reduces Cardiac and Brain Inflammation in Rats Fed a HFD and Exposed to Chronic Mental Stress through NF-κB Inhibition.

Authors:  Lijun Zhang; Guo Li; Shuhui Tao; Pengyan Xia; Naveed Chaudhry; Shawn Kaura; Sara Saymuah Stone; Meiyan Liu
Journal:  Mediators Inflamm       Date:  2022-05-29       Impact factor: 4.529

2.  Ginkgolide J protects human synovial cells SW982 via suppression of p38‑dependent production of pro‑inflammatory mediators.

Authors:  Yujie Zhao; Yuan Chen; Jiayi Wang; Xue Zhu; Ke Wang; Yue Li; Fanfan Zhou
Journal:  Mol Med Rep       Date:  2021-06-03       Impact factor: 2.952

Review 3.  Neuroprotection in Glaucoma.

Authors:  Azadeh Doozandeh; Shahin Yazdani
Journal:  J Ophthalmic Vis Res       Date:  2016 Apr-Jun

Review 4.  Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs.

Authors:  Matěj Malík; Pavel Tlustoš
Journal:  Nutrients       Date:  2022-08-17       Impact factor: 6.706

5.  Targeted preventive measures and advanced approaches in personalised treatment of glaucoma neuropathy.

Authors:  Maneli Mozaffarieh; Stefan Fraenkl; Katarzyna Konieczka; Josef Flammer
Journal:  EPMA J       Date:  2010-06-10       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.